Drug Profile


Alternative Names: 226256-56-0; AMG-073; Cinacalcet hydrochloride; KRN-1493; Mimpara; NPS-1493; Regpara; Sensipar

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator NPS Pharmaceuticals
  • Developer Amgen; Kirin Holdings Company
  • Class Naphthalenes
  • Mechanism of Action Calcium channel agonists; Parathyroid hormone receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypercalcaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypercalcaemia; Primary hyperparathyroidism; Secondary hyperparathyroidism
  • No development reported Cardiovascular disorders

Most Recent Events

  • 14 Feb 2017 Amgen has patent protection for cinacalcet in USA and European Union (Amgen 10-K, February 2017)
  • 21 Oct 2016 Preregistration for Secondary hyperparathyroidism in Brunei (PO) (Kyowa Hakko Kirin pipeline, October 2016)
  • 22 Jun 2016 Amgen terminates a phase II trial in Secondary hyperparathyroidism (In children, In adolescents) in USA, Belgium, Czech Republic, France, Germany, Hungary, Italy, Mexico, the Netherlands, New Zealand, Poland, Russia and Slovakia (NCT01439867)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top